West Pharmaceutical Services (WST)

Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive — consensus sits at a manageable bar after the blowout Q1 print, guidance was raised to 7–9% organic growth for the full year, and the biggest swing factor is whether Non-GLP-1 HVP Components can sustain the high-teens momentum that drove Q1 outperformance.

Heading into Q2 2026, West Pharmaceutical Services carries significant positive momentum from a blowout Q1 print — 15% organic revenue growth, ~350 bps of operating margin expansion, and ~47% EPS growth — that prompted management to raise full-year organic growth guidance to 7–9% (the long-term construct range) from 5–7%, and lift adjusted EPS guidance to $8.40–$8.75. Consensus for Q2 sits at ~$842.7M in revenue and ~$2.09 in adjusted EPS, implying ~8.7% organic growth — a step-down from Q1's 15% pace that management explicitly guided to (7–9.6% organic for Q2), making the bar achievable but not trivially easy. Estimate revisions have been essentially flat since the post-Q1 baseline, suggesting the Street has largely digested the guidance raise without adding incremental cushion. The stock has rallied ~16% since the Q1 print (vs. XLV +9%), trading at ~39x NTM P/E and ~26x NTM EV/EBITDA — a premium that prices in continued execution but leaves limited room for a miss. The key wildcard is the CGM contract roll-off at Dublin West Vantage (a ~$40M H2 headwind) and whether drug handling revenue ramps fast enough to offset it — a dynamic that will be most visible in Q3 but whose trajectory management will likely frame on the Q2 call. A secondary wildcard is the cybersecurity incident from May 4–20, which was fully resolved per the May 20 8-K/A with guidance maintained, but any residual operational or financial disclosure could surprise.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable bar at ~8.7% organic growth and ~$2.09 adjusted EPS — both within the guided range. HVP Components revenue is the bigger swing factor; any acceleration above the ~$414M consensus estimate would signal Non-GLP-1 momentum is holding, while a miss would raise questions about Q1 pull-forward.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data (Total Revenue, HVP Components, Adj. EPS, Adj. Operating Income); Q1 2026 Earnings Call transcript (April 23, 2026) for Q2 and FY guidance ranges.

Table 2 — Beat/Miss History (Last 8 Quarters)

Top KPI 1: Total Revenue

Top KPI 2: Adjusted Diluted EPS

Pattern: WST has beaten consensus on both revenue and adjusted EPS in every reported quarter over the trailing seven periods, with EPS beats averaging ~17% — a consistent pattern of conservative guidance that sets a low bar for the Street. The Q1 2026 EPS beat of +26% was the largest in the series, driven by Non-GLP-1 HVP acceleration and operational leverage at Eschweiler.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised full-year guidance materially at Q1 earnings (April 23) and has not revised it since — the May cybersecurity incident was resolved with guidance maintained. Tone is constructive and more specific than prior quarters, with management providing granular sub-segment growth targets and flagging the CGM roll-off as a known H2 headwind.

Source: Q1 2026 Earnings Call transcript (April 23, 2026); WST 8-K filed May 11, 2026; WST 8-K/A filed May 20, 2026; Visible Alpha Consensus and Actuals Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been essentially flat since the post-Q1 baseline — the Street absorbed the guidance raise without adding incremental cushion. The lack of upward revision drift despite a blowout Q1 suggests the bar is not being inflated, which is a favorable setup for another beat if demand trends hold.

Estimates have been remarkably stable since the post-Q1 baseline — essentially no revision drift in either direction over the ~12 weeks since the print. This is unusual given the magnitude of the Q1 beat and guidance raise, and suggests the Street is treating the guidance range as the ceiling rather than a floor. If WST delivers another beat (consistent with its 7-quarter track record), the lack of pre-print estimate inflation means the positive surprise would be incremental rather than already priced in.

Source: Visible Alpha Consensus and Actuals Data (revision history table, weekly frequency, May 1 – July 22, 2026).

5. Stock Performance

Key Takeaway: WST has outperformed both XLV and the S&P 500 by a wide margin since the Q1 print, with the rally driven almost entirely by multiple expansion (NTM EV/EBITDA expanded from ~21.9x to ~26.1x, +19%) rather than estimate revisions (which were flat). The stock is up ~16% since April 23 vs. XLV +9% and SPY +5%, suggesting sentiment and re-rating are doing the heavy lifting.

[Image not found: gs://lum-us-east4-prod-chat-tool-outputs/conversations/2026-07-22/conv_01k0aqhqhkfhqbqhqhqhqhqhq/plotly_charts/wst_stock_performance.json]

WST vs. XLV vs. S&P 500 — Indexed to 100 at April 23, 2026 (Q1 2026 Earnings Date). Source: Yahoo Finance / Stock Price Data.

Selected Indexed Performance (Base = 100 at April 23, 2026 Q1 Earnings Date):

Performance Summary: WST +15.9% | XLV +9.0% | SPY +5.6% since Q1 earnings. WST outperformed XLV by ~690 bps and SPY by ~1,030 bps. The cyberattack (May 11) caused a ~3% drawdown vs. the post-Q1 peak, but the stock fully recovered within two weeks after the May 20 resolution. The CEO succession announcement (June 1) was a non-event for the stock. The bulk of the outperformance vs. XLV occurred in June–July as the market re-rated WST on the strength of the biologics/GLP-1 demand backdrop.

Source: Yahoo Finance / Stock Price Data. NTM multiple data from internal stock performance decomposition tool.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the CEO succession (Michel Lagarde, effective August 31) — a CDMO/pharma services veteran whose appointment signals strategic continuity and potentially accelerated execution on the West Vantage drug handling pivot. The cybersecurity incident was fully resolved with no guidance impact.

• July 14, 2026 — Daikyo Seiko Partnership Renewal (8-K): WST renewed its Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements with Daikyo Seiko, Ltd. (WST holds 49% ownership in Daikyo), effective July 14, 2026, for a 10-year term. Terms are substantially similar to the prior 2017 agreements.
• Implication: Secures WST’s exclusive distribution rights for Daikyo products outside Japan and reinforces the long-term strategic partnership underpinning WST’s FluroTec and NovaPure product lines. A 10-year term provides multi-cycle revenue visibility.
• June 1, 2026 — CEO Succession: Michel Lagarde Named Incoming CEO (8-K): Michel Lagarde (age 52), former EVP & COO of Thermo Fisher Scientific and former President & COO of Patheon N.V., was appointed President and CEO effective August 31, 2026. Eric Green will retire and resign from the Board on the same date. Robert Friel (Lead Independent Director) will become Board Chair. Lagarde’s compensation includes $1.175M base salary, 125% target bonus, and $10M LTI target.
• Implication: Lagarde’s CDMO and pharma services background is a strong strategic fit for the West Vantage drug handling pivot. His Patheon/Thermo Fisher experience in complex biologics manufacturing is directly relevant. The market received the announcement constructively (stock was flat to slightly up on June 2).
• May 20, 2026 — Cybersecurity Incident Fully Resolved (8-K/A): WST confirmed full restoration of all global operations following the May 4 cyberattack. Guidance was maintained. The company confirmed exfiltrated data was de-encrypted and no additional data loss occurred.
• Implication: Removes the operational uncertainty that existed at the May 12 BofA conference. No financial impact was quantified, and the Q2 print will be the first opportunity to assess any residual revenue timing effects from the ~2-week disruption.
• May 11, 2026 — Material Cybersecurity Incident Disclosed (8-K): WST disclosed a material cyberattack detected May 4, involving data exfiltration and system encryption. The company shut down systems globally, engaged Palo Alto Networks Unit 42, and notified law enforcement. Stock declined ~3% on May 12.
• Implication: Fully resolved per May 20 8-K/A. Watch for any Q2 revenue timing impact disclosure on the July 23 call.
• April 23, 2026 — Q1 2026 Blowout Earnings & Guidance Raise: Revenue of $844.9M (+15.3% organic), Adj. EPS of $2.13 (+26% vs. consensus). Full-year organic growth guidance raised to 7–9% from 5–7%. New $X share repurchase authorization. Board authorized new buyback program.
• Implication: Sets the baseline for Q2 expectations. Non-GLP-1 HVP acceleration to high-teens was the key surprise; sustainability of that trend is the central debate heading into Q2.

7. Peer Commentary & Read-Throughs (May 23 – July 22, 2026)

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for WST’s Q2 print. Danaher’s mid-teens order growth in bioprocessing consumables and Lonza’s upgraded EBITDA margin outlook are the strongest direct demand signals. Gerresheimer’s guidance cut is a company-specific execution risk, not a demand signal, and is a negative read-through for WST only if production ramp-up challenges are industry-wide — which Danaher and Lonza data suggest they are not. Stevanato’s GLP-1 and biologics commentary is the most directly comparable to WST’s HVP growth thesis.

Scope: Only commentary disclosed May 23–July 22, 2026 that explicitly addresses WST’s current reporting period (Q2 2026) or forward periods is included. Commentary confined to peers’ own completed prior quarters is excluded.

7.1 Danaher (DHR) — Q2 2026 Earnings Call, July 21, 2026

Read-Through Type: Direct — Demand Signal (Bioprocessing / Biologics)

• Bioprocessing order growth remained robust despite a revenue timing miss: Danaher reported mid-teens order growth in both bioprocessing consumables and equipment in Q2 2026, even as revenue was impacted by ~$100M+ of large chromatography resin shipments pushed out of Q2/Q3 into 2027 due to customer production schedule changes and site readiness challenges. Management characterized the push-outs as timing, not demand, and said it is “highly unlikely” these orders will not ship in 2027.
• WST Read-Through: Mid-teens order growth in bioprocessing consumables is a strong positive signal for WST’s Non-GLP-1 HVP Components business, which is driven by biologics and biosimilar demand. The distinction between order strength and revenue timing is important — it suggests underlying demand for injectable biologics is healthy, even if some large-batch manufacturing schedules shifted. WST’s elastomer components are consumed at the point of fill, so any delay in large-batch resin shipments could create a modest timing lag for WST as well, but the order pipeline signal is constructive.
• Biotech funding improving: Danaher noted that improved biotech funding is now translating from funnel activity to orders and, “on the margins,” to revenue. Large pharma and biopharma demand remained healthy.
• WST Read-Through: Improved biotech funding is a leading indicator for new molecule development and eventual commercialization, which drives WST’s long-term HVP Components pipeline. Near-term impact on Q2 is limited, but it supports the multi-year growth thesis.
• Onshoring / reshoring CapEx cycle in early innings: Danaher stated it believes it is “in the early innings of a multi-year CapEx cycle” to support growing biologic volumes and reshoring. Equipment revenue growth was cited as a signal of brownfield expansion beginning to flow through.
• WST Read-Through: Reshoring of biologic manufacturing to the US is a direct tailwind for WST, which has been executing tech transfers from European plants to US facilities (Kinston, Jersey Shore) to help customers achieve local-for-local manufacturing. This dynamic supports WST’s capacity utilization narrative and validates the Annex 1 geographic expansion thesis.
• Q3 2026 guidance: +2–3% total revenue growth, implying ~5% core ex-respiratory: Danaher guided Q3 core growth (ex-respiratory) of ~5%, an acceleration vs. Q2, with a mid-single digit exit rate in Q4.
• WST Read-Through: Accelerating core growth at Danaher through H2 2026 is consistent with WST’s own guidance for continued HVP momentum. The trajectory supports the view that the biologics market is recovering, not plateauing.

7.2 Lonza Group — H1 2026 Results, July 22, 2026

Read-Through Type: Direct — Demand Signal (CDMO / Biologics / Injectable Drug Manufacturing)

• Strong H1 2026 performance with upgraded margin outlook: Lonza reported H1 2026 sales of CHF 3.4B (+16.0% CER), CORE EBITDA of CHF 1.175B (+27.4%), and upgraded its full-year CORE EBITDA margin outlook to 33–34% (from “above 32%”). Full-year CER sales growth guidance of 11–12% was maintained.
• WST Read-Through: Lonza’s strong H1 biologics manufacturing performance directly validates the demand environment for injectable drug components. As a leading CDMO, Lonza’s commercial production volumes are a leading indicator for WST’s elastomer and closure demand. The upgraded margin outlook suggests Lonza is not experiencing the production ramp-up difficulties seen at Gerresheimer, which is a positive read-through for WST’s own operational execution narrative.
• H2 2026 growth expected to moderate due to tougher comps and phasing: Lonza cautioned that H2 sales growth will moderate vs. H1 due to a higher prior-year base and favorable H1 phasing, particularly in Advanced Synthesis. Margins will also normalize in H2 from a less favorable product mix.
• WST Read-Through: The H2 moderation at Lonza is primarily a comp and phasing issue, not a demand deterioration. For WST, this is a mild caution signal — if large-batch biologics production schedules shift to H1-weighted, WST’s H2 HVP component demand could face a similar (though likely smaller) comp headwind. This is consistent with WST’s own guidance that Q3 will be the West Vantage trough.
• Sustained commercial demand across large pharma and biotech: Lonza described “healthy momentum in strategic outsourcing activities across both large pharma and biotech customers” and characterized the pipeline as “robust.” A new long-term collaboration with a leading US biopharma for a broad portfolio of clinical and commercial biologics was announced.
• WST Read-Through: Sustained outsourcing momentum and new long-term biologics manufacturing commitments are direct demand signals for WST’s HVP Components. New commercial biologics programs require validated, high-quality elastomer components — WST’s core product.
• Cell & Gene strengthening toward end of H1, expected to support H2 growth: Lonza noted strengthened operational performance in Cell & Gene toward the end of H1 2026, with better growth momentum anticipated in H2.
• WST Read-Through: Cell & Gene therapies are predominantly injectable and require specialized containment solutions. Improving C&G production volumes at Lonza are a positive leading indicator for WST’s participation in this high-value segment.

7.3 Intuitive Surgical (ISRG) — Q2 2026 Earnings Call, July 16, 2026

Read-Through Type: Indirect — Demand Signal (Surgical Procedure Volume / Hospital Capital Spending)

• Full-year 2026 Da Vinci procedure growth maintained at 13.5–15.5%, closer to midpoint: ISRG maintained its full-year procedure growth forecast, with primary drivers being US general surgery and international non-urology procedures. The US capital environment was described as “stable” with a healthy pipeline.
• WST Read-Through: Stable and growing surgical procedure volumes support demand for injectable drugs administered peri-operatively (anesthesia, biologics, supportive care), which in turn drives demand for WST’s elastomer components. This is an indirect signal — ISRG’s procedure growth does not directly consume WST products, but it reflects a healthy hospital capital and procedure environment that is broadly supportive of injectable drug demand.
• Japan reimbursement changes effective June 1 driving increased system placements: New Japanese policies supporting robotic surgery went into effect June 1, including reimbursement for additional procedures and economic incentives for higher utilization. ISRG saw increased system placements in Japan in Q2.
• WST Read-Through: Japan is a growing market for WST’s HVP Components, particularly for biologics and biosimilars. Increased surgical procedure adoption in Japan is a mild positive for the broader injectable drug market in the region.
• Q3 US procedure growth faces a tougher comp; international seasonal shifts: ISRG flagged a “little bit of a tougher comp in the US in Q3” and noted seasonal holiday movements that shifted from Q4 to Q3 last year, creating a modest headwind internationally in Q3/Q4.
• WST Read-Through: Modest procedure volume headwinds in Q3 are a minor indirect negative for WST’s peri-operative injectable demand, but the magnitude is small and the primary WST growth drivers (GLP-1, biologics, Annex 1) are not procedure-volume dependent.

7.4 Gerresheimer — 2026 Guidance Cut, June 29, 2026

Read-Through Type: Indirect — Company-Specific Execution Risk (Medical Packaging / Production Ramp-Up)

• Gerresheimer cut its 2026 EBITDA margin outlook to 17–18% (from 18–19%) and guided to negative free cash flow of €-50M to €-100M: The company cited project delays, operational issues, and production ramp-up challenges as the primary drivers. Revenue guidance was maintained in the lower half of the €2.3–2.4B range.
• WST Read-Through: This is a company-specific execution risk, not a demand signal. Gerresheimer’s challenges appear to be internal — production ramp-up difficulties and project delays — rather than a reflection of weak end-market demand. Importantly, Danaher and Lonza data from the same period show robust underlying biologics demand, which argues against a broad industry demand slowdown. For WST, the read-through is a mild caution on production ramp-up complexity (WST is also ramping capacity at Eschweiler, Kinston, and Jersey Shore), but WST’s Q1 2026 results and management commentary suggest its own ramp-up execution has been better than anticipated. The Gerresheimer miss is a reminder that execution risk is real in this sector, but it is not a demand read-through.
• Key distinction: Gerresheimer produces glass vials and syringes (primary packaging), while WST produces elastomer closures and drug delivery devices. The competitive overlap is limited, and the operational challenges at Gerresheimer do not directly translate to WST’s manufacturing processes.

7.5 Stevanato Group (STVN) — William Blair Conference (June 2) & Jefferies Conference (June 4, 2026)

Read-Through Type: Direct — Demand Signal (GLP-1 / Biologics / High-Value Drug Containment)

• GLP-1 revenue growing >20% YoY in Q1 2026, representing 21–22% of total revenue: Stevanato reported GLP-1 revenue growing over 20% year-over-year in Q1 2026, with syringes as the dominant primary packaging configuration. The company is actively expanding into cartridges-to-fill, with the first high-speed cartridge line starting in Latina in June/July 2026.
• WST Read-Through: Stevanato’s GLP-1 growth trajectory is directly comparable to WST’s GLP-1 HVP Components business. Both companies serve the same GLP-1 originator customers (Novo Nordisk, Eli Lilly) and biosimilar pipeline. Stevanato’s >20% GLP-1 growth in Q1 is consistent with WST’s own >40% GLP-1 HVP growth in Q1 (WST’s higher growth rate reflects its elastomer content per device vs. Stevanato’s glass container). The cartridge-to-fill expansion at Stevanato is a positive signal for WST’s elastomer demand, as cartridges require WST’s plungers and seals.
• Biologics market growing double digits; 10,000 molecules in Phase 2/3 globally: Stevanato described the biologics market as “growing double digit” and highlighted increasing demand for sophisticated coatings, large-volume syringes, and cartridges. The company noted that >60% of pipeline molecules will be delivered via injection or self-medication.
• WST Read-Through: This is a strong direct demand signal for WST’s Non-GLP-1 HVP Components business. The 10,000-molecule biologics pipeline is the same pipeline that drives WST’s NovaPure and Daikyo FluroTec demand. Stevanato’s double-digit biologics growth in Q1 is consistent with WST’s high-teens Non-GLP-1 HVP growth.
• Customer CapEx project conversion taking longer; pipeline healthy but orders delayed 1–2 quarters: Stevanato noted that while the pipeline of customer CapEx projects is healthy, conversion into orders is taking more time as customers validate initial lines before committing to subsequent ones.
• WST Read-Through: This is a mild caution signal for WST’s West Vantage drug handling business, which is in the early stages of ramping new customer programs. However, WST’s core HVP Components business is driven by consumable demand (elastomers per fill), not capital project orders, so the Stevanato project timing issue is less directly applicable to WST’s near-term revenue.
• Annex 1 driving bulk-to-ready-to-fill conversion; outsourcing trend accelerating: Stevanato described Annex 1 as requiring “more sophisticated quality requirements” and noted a trend of pharmaceutical companies outsourcing washing, siliconization, and sterilization processes due to total cost of ownership benefits. A major client is converting all platforms from bulk to ready-to-fill over 5–6 years.
• WST Read-Through: This is a direct validation of WST’s Annex 1 conversion thesis. The outsourcing trend described by Stevanato mirrors WST’s own narrative of customers upgrading from standard to HVP components driven by Annex 1 compliance requirements. The 5–6 year conversion timeline at a major Stevanato client is consistent with WST’s characterization of the Annex 1 opportunity as a multi-year runway.

7.6 Abbott Laboratories (ABT) — Q2 2026 Earnings Call, July 16, 2026

Read-Through Type: Indirect — Demand Signal (Biosimilars / Injectable Drug Pipeline / Hospital Capital)

• Abbott reaffirmed full-year comparable sales growth of 6.5–7.5% and raised EPS guidance to $5.45–$5.60: Management expressed confidence in H2 2026 acceleration, citing momentum across the portfolio and clear line of sight to growth drivers.
• WST Read-Through: Abbott’s confidence in H2 2026 acceleration reflects a healthy medical device and diagnostics market, which is broadly supportive of injectable drug demand. Abbott is not a direct WST customer in the same way as large pharma biologics manufacturers, but its positive H2 outlook is a constructive macro signal.
• Expanding biosimilar pipeline in Established Pharmaceuticals (EPD): Abbott cited an “expanding pipeline of biosimilars” as a structural tailwind for its EPD segment, positioning it for “high single digit sales growth.”
• WST Read-Through: Biosimilar pipeline expansion is a direct positive for WST’s Non-GLP-1 HVP Components business. New biosimilar approvals require validated, high-quality elastomer components, and WST’s >90% participation rate in new biologic approvals positions it to capture this demand.
• Fifth CGM manufacturing facility in planning stages ($1B investment): Abbott disclosed it is in the “final stages of planning” for a fifth CGM sensor manufacturing facility, a ~$1B investment, due to anticipated capacity constraints in the next couple of years.
• WST Read-Through: This is a notable indirect signal. WST’s Dublin West Vantage facility is exiting the CGM contract (Abbott’s FreeStyle Libre CGM) at end of Q2 2026. Abbott’s announcement of a fifth CGM facility confirms the long-term growth trajectory of the CGM market, but WST has already exited this contract and is pivoting to drug handling. The Abbott CGM expansion does not create a re-entry opportunity for WST in the near term.

Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: Only two insider transactions were filed since the Q1 earnings date — both discretionary open-market sales by senior officers on April 27, 2026, four days after the Q1 print. No open-market buys were filed; the sales are modest in size relative to holdings and are not flagged as 10b5-1 planned sales, suggesting opportunistic selling into the post-earnings rally rather than a bearish signal.

Assessment: The two sales are small in absolute dollar terms (at ~$300/share, Favorite’s sale was ~$845K and Winters’ was ~$269K) and occurred in the immediate post-earnings window when insiders are typically permitted to trade. Neither is flagged as a 10b5-1 planned sale. The absence of any open-market buys — despite the stock being up ~16% since the print — is notable but not alarming given the stock’s premium valuation. No CEO or CFO transactions were filed. The incoming CEO (Michel Lagarde) has a contractual incentive to purchase WST stock between May 31 and August 31, 2026 (matching inducement grants up to $2.5M), which could represent a positive insider signal if disclosed before or at the Q2 print.

Source: SEC Form 4 Filings Database (Insider Transaction Data). Form 4 filings: Annette F. Favorite (filed Apr 29, 2026); Chad Winters (filed Apr 29, 2026).